Geode Capital Management LLC Raises Position in Shattuck Labs, Inc. (NASDAQ:STTK)

Geode Capital Management LLC grew its stake in shares of Shattuck Labs, Inc. (NASDAQ:STTK) by 0.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 912,202 shares of the company’s stock after acquiring an additional 8,133 shares during the quarter. Geode Capital Management LLC owned about 1.91% of Shattuck Labs worth $3,184,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Renaissance Technologies LLC raised its stake in Shattuck Labs by 83.1% during the 2nd quarter. Renaissance Technologies LLC now owns 392,010 shares of the company’s stock worth $1,513,000 after acquiring an additional 177,910 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Shattuck Labs by 209.7% during the second quarter. Bank of New York Mellon Corp now owns 222,034 shares of the company’s stock valued at $857,000 after buying an additional 150,340 shares during the period. Villere ST Denis J & Co. LLC increased its stake in Shattuck Labs by 83.7% in the third quarter. Villere ST Denis J & Co. LLC now owns 132,600 shares of the company’s stock worth $463,000 after purchasing an additional 60,400 shares during the period. State Street Corp increased its stake in Shattuck Labs by 7.8% in the 3rd quarter. State Street Corp now owns 766,410 shares of the company’s stock worth $2,675,000 after buying an additional 55,579 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Shattuck Labs by 44.1% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 178,228 shares of the company’s stock valued at $622,000 after purchasing an additional 54,505 shares during the period. 58.74% of the stock is owned by institutional investors.

Shattuck Labs Price Performance

STTK stock opened at $1.27 on Tuesday. The company has a market cap of $60.63 million, a price-to-earnings ratio of -0.83 and a beta of 1.71. The company has a fifty day moving average price of $1.18 and a 200 day moving average price of $2.50. Shattuck Labs, Inc. has a 12 month low of $0.94 and a 12 month high of $11.76.

Insider Activity at Shattuck Labs

In other news, Director Redmile Group, Llc acquired 133,371 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was purchased at an average cost of $1.25 per share, with a total value of $166,713.75. Following the purchase, the director now directly owns 5,539,724 shares of the company’s stock, valued at approximately $6,924,655. This trade represents a 2.47 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. 10.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on STTK shares. HC Wainwright reiterated a “neutral” rating on shares of Shattuck Labs in a report on Friday, November 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Shattuck Labs in a research report on Thursday, November 14th. Evercore ISI raised shares of Shattuck Labs to a “strong-buy” rating in a report on Wednesday, October 2nd. Finally, Citigroup cut shares of Shattuck Labs from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $8.00 to $2.00 in a research note on Wednesday, October 2nd. Four investment analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $8.67.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.